Johnston Sara C, Ricks Keersten M, Lakhal-Naouar Ines, Jay Alexandra, Subra Caroline, Raymond Jo Lynne, King Hannah A D, Rossi Franco, Clements Tamara L, Fetterer David, Tostenson Samantha, Cincotta Camila Macedo, Hack Holly R, Kuklis Caitlin, Soman Sandrine, King Jocelyn, Peachman Kristina K, Kim Dohoon, Chen Wei-Hung, Sankhala Rajeshwer S, Martinez Elizabeth J, Hajduczki Agnes, Chang William C, Choe Misook, Thomas Paul V, Peterson Caroline E, Anderson Alexander, Swafford Isabella, Currier Jeffrey R, Paquin-Proulx Dominic, Jagodzinski Linda L, Matyas Gary R, Rao Mangala, Gromowski Gregory D, Peel Sheila A, White Lauren, Smith Jeffrey M, Hooper Jay W, Michael Nelson L, Modjarrad Kayvon, Joyce M Gordon, Nalca Aysegul, Bolton Diane L, Pitt Margaret L M
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Vaccines (Basel). 2022 May 4;10(5):717. doi: 10.3390/vaccines10050717.
The COVID-19 pandemic has had a staggering impact on social, economic, and public health systems worldwide. Vaccine development and mobilization against SARS-CoV-2 (the etiologic agent of COVID-19) has been rapid. However, novel strategies are still necessary to slow the pandemic, and this includes new approaches to vaccine development and/or delivery that will improve vaccination compliance and demonstrate efficacy against emerging variants. Here, we report on the immunogenicity and efficacy of a SARS-CoV-2 vaccine comprising stabilized, pre-fusion spike protein trimers displayed on a ferritin nanoparticle (SpFN) adjuvanted with either conventional aluminum hydroxide or the Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque COVID-19 model. Vaccination resulted in robust cell-mediated and humoral responses and a significant reduction in lung lesions following SARS-CoV-2 infection. The strength of the immune response suggests that dose sparing through reduced or single dosing in primates may be possible with this vaccine. Overall, the data support further evaluation of SpFN as a SARS-CoV-2 protein-based vaccine candidate with attention to fractional dosing and schedule optimization.
新冠疫情对全球社会、经济和公共卫生系统产生了惊人的影响。针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2，新冠病毒的病原体）的疫苗研发和推广速度很快。然而，仍需要新的策略来减缓疫情传播，这包括疫苗研发和/或接种的新方法，这些方法将提高疫苗接种的依从性，并证明对新出现的病毒变种有效。在此，我们报告了一种SARS-CoV-2疫苗在食蟹猕猴新冠模型中的免疫原性和有效性，该疫苗由展示在铁蛋白纳米颗粒上的稳定化、前融合刺突蛋白三聚体（SpFN）组成，佐剂为传统的氢氧化铝或陆军脂质体制剂QS-21（ALFQ）。接种疫苗后产生了强烈的细胞介导免疫和体液免疫反应，并显著减少了SARS-CoV-2感染后的肺部损伤。免疫反应的强度表明，这种疫苗在灵长类动物中通过减少剂量或单次给药来节省剂量可能是可行的。总体而言，这些数据支持进一步评估SpFN作为一种基于SARS-CoV-2蛋白的疫苗候选物，同时关注分剂量给药和接种方案优化。
